COPD (Chronic Obstructive Pulmonary Disease) inhalation therapy is a direct drug delivery method targeting the lungs, primarily through inhalation devices that deliver medication to the airways and alveoli. The core goal of this therapy is to relieve bronchoconstriction, reduce inflammatory responses, and improve patients' breathing difficulties. Because the medication acts directly on the affected areas, it effectively lowers systemic side effects, making it a fundamental long-term management strategy for COPD.
Using different types of inhalation devices combined with various medications, physicians tailor personalized treatment plans based on the extent of lung function impairment and symptom severity. This therapy not only controls the frequency of acute exacerbations but also slows disease progression and enhances patients’ tolerance for daily activities.
COPD inhalation therapy mainly involves three categories of drugs: bronchodilators, corticosteroids, and anticholinergic agents. Bronchodilators like Salmeterol relax airway smooth muscle, while anti-inflammatory corticosteroids such as Budesonide inhibit the release of inflammatory mediators, thereby slowing lung tissue destruction.
Devices include Metered Dose Inhalers (MDI), Dry Powder Inhalers (DPI), and nebulizers. DPI requires active inhalation by the patient, whereas nebulizers are suitable for patients with severe respiratory failure. Combination drugs like ICS/LABA (inhaled corticosteroids combined with long-acting beta-agonists) address both airway narrowing and chronic inflammation simultaneously, enhancing overall treatment efficacy.
This therapy is suitable for COPD patients at all stages, especially those with moderate to severe symptoms. During acute exacerbations, short-acting bronchodilators (SABA/SAMA) are used for rapid symptom relief. During stable periods, long-acting medications (LABA/LAMA) are used to maintain baseline control.
It is also applicable to patients with overlap syndrome of asthma and COPD (ACOS), but corticosteroid use should be adjusted based on inflammation markers. Physicians select single or combination drug regimens based on lung function tests (such as FEV1 values) and symptom severity.
MDIs require the use of a spacer device. Operation steps include shaking the inhaler, exhaling fully before aiming the mouthpiece, inhaling slowly while pressing the inhaler, and holding breath for about 5-10 seconds to allow medication deposition. DPI requires steady inhalation to activate the powder. After use, rinsing the mouth prevents oral candidiasis.
Dosage adjustments follow the "stepwise therapy" principle: mild patients may use once daily, while moderate to severe patients may use dual or triple therapy. Doctors adjust doses based on six-minute walk tests or symptom diaries. Patients should not self-adjust medication doses.
Inhaled medications act directly on the respiratory tract and can provide rapid relief (within 15-30 minutes). Compared to oral medications, inhaled forms have systemic absorption rates below 10%, significantly reducing the risk of side effects such as osteoporosis caused by steroids.
Clinical studies show that regular use of inhalation therapy can reduce ICU admissions by 40% and decrease acute exacerbations by 25% within one year. Its portability and ease of use also improve patient adherence, aiding long-term disease control.
Common side effects include dry mouth, hoarseness, and throat irritation, occurring in about 20-30% of patients. Long-term steroid use may cause oral candidiasis or vocal cord dysfunction; rinsing the mouth after each use is recommended.
Serious side effects include palpitations and decreased blood potassium levels, especially when combined with beta-2 agonists, requiring blood pressure monitoring. Rarely, patients may develop drug resistance, necessitating regular peak expiratory flow measurements to evaluate efficacy.
Contraindications include severe allergies to drug components, uncontrolled hyperthyroidism, and conditions that may worsen bronchospasm. Patients with arrhythmias or electrolyte imbalances require enhanced monitoring. Use during pregnancy should weigh maternal and fetal risks.
Environmental factors to note include low temperatures, which may affect spray uniformity, and high humidity, which can increase airway irritation. Use should be avoided in dusty or allergen-rich environments to prevent bronchospasm.
Combining with beta-blockers may reduce efficacy; dose adjustments or use of selective beta-1 blockers are recommended. Diuretics may exacerbate hypokalemia caused by inhaled beta-2 agonists; regular electrolyte monitoring is advised.
When used with oral steroids, bone density should be monitored, and calcium and vitamin D supplements are recommended for long-term users. Central nervous system depressants may impair proper inhaler operation, so family supervision is advised.
Multicenter studies show that regular use of LABA/ICS combinations can improve FEV1 by an average of 12-15% and reduce severe exacerbations by 34%. Long-term follow-up indicates that inhalation therapy can slow the annual decline in lung function by 25%.
The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report states that triple therapy (LABA/LAMA/ICS) can improve the six-minute walk distance by 50-80 meters in patients with severe airway obstruction. Clinical trials confirm that inhaled PDE4 inhibitors can reduce mucus hypersecretion by 30%.
Patients unable to properly operate inhalers may switch to nebulized inhalation therapy, but maintenance of the machine is necessary to prevent bacterial contamination. Severe lung impairment may require oral theophylline or anti-fibrotic drugs, though the latter carries a higher risk of hepatotoxicity.
Surgical options such as lung volume reduction surgery or lung transplantation are reserved for end-stage patients and carry higher risks. Oxygen therapy can be used as an adjunct but cannot replace the anti-inflammatory and bronchodilatory effects of medications.
A: When using an inhaler, follow four steps: 1. Exhale completely to residual volume before inhalation, 2. Press the inhaler while slowly inhaling to synchronize inhalation, 3. Hold your breath for about 5-10 seconds to allow medication deposition, 4. Rinse your mouth with water to remove residual medication. Beginners are advised to practice in front of a mirror or use a spacer to improve drug deposition efficiency.
Q: Will long-term use of bronchodilator inhalers lead to drug resistance?A: There is no evidence that bronchodilators such as anticholinergic agents or long-acting beta-agonists cause resistance in COPD. However, caution is needed: 1. Overuse of rescue short-acting inhalers may trigger symptom worsening, 2. If drug efficacy seems reduced, seek medical attention immediately, as it may indicate worsening lung function rather than resistance. Physicians will adjust treatment based on lung function tests.
Q: How to assess the risk of oral candidiasis during inhaled steroid therapy?A: Patients on long-term inhaled steroids should have their oral mucosa checked every 2-3 months. Signs include white patches on the tongue or cheeks, painful swallowing, or persistent sore throat, which may indicate candidiasis. Rinsing the mouth thoroughly after each use and using antimicrobial mouthwash can prevent infection. If diagnosed, doctors may prescribe short-term oral antifungal medication and temporarily discontinue steroids.
Q: What are the differences in inhaler medication strategies between acute exacerbations and stable periods?A: During stable periods, the focus is on controlling symptoms with long-acting bronchodilators or low-dose corticosteroid inhalers. During acute exacerbations, the frequency of short-acting rescue inhalers increases, and short-term oral corticosteroids are used. The key difference is that stable management emphasizes regular use of maintenance medications, while exacerbations require short-term intensified treatment and immediate medical evaluation. Patients should follow their physician’s instructions carefully and avoid self-adjusting doses.
Q: Should I stop using the inhaler if I experience hoarseness or increased coughing?A: Hoarseness is often caused by medication residue irritating the throat and can be reduced by using a "spaced inhalation" method (dividing the dose into 2-3 inhalations) or using a valved spacer. Persistent cough lasting more than three days may be a bronchial hypersensitivity reaction; doctors may recommend switching to a different inhaler type (such as DPI) or adding antihistamines. Only in cases of severe airway irritation or wheezing should therapy be temporarily discontinued. Most patients can continue treatment after adjusting their inhalation technique.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
